VRML Vermillion

Vermillion to Participate in Statewide “Women and Girls Day” at the Connecticut State Capital on March 6, 2020

Vermillion to Participate in Statewide “Women and Girls Day” at the Connecticut State Capital on March 6, 2020

AUSTIN, Texas, March 04, 2020 (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced Valerie Palmieri will participate on a Women in Leadership Panel, representing the corporate sector, at “Women and Girls Day” at the Connecticut State Capital. The all-day event is in celebration of Women’s History Month and the 100th anniversary of women’s suffrage. The company will also have an education booth on site for OVA1 Plus and overall Ovarian Cancer Awareness.

The event, hosted by the State of Connecticut, will be moderated by Melissa McCaw, Secretary of the Office of Policy and Management for the State of Connecticut and will feature topics critical to women’s health. Other participants in the panel include: Susan Bysiewicz, Lieutenant Governor for the State of Connecticut; Dr. Elsa Núñez, President of Eastern Connecticut State University; and Fran Pastore, CEO and Founder of Women’s Business Development Council.

“We are very honored to participate in this prestigious event and to be recognized by the Governor and Lt. Governor from the State of Connecticut for our commitment to women’s health,” said Valerie Palmieri, CEO of Vermillion, Inc.

About Vermillion, Inc.

Vermillion, Inc. is transforming women’s health with the discovery, development and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1®plus combines our FDA-cleared products OVA1® and OVERA® to detect risk of ovarian malignancy in women with adnexal masses. Recently launched, ASPiRA GenetiXSM testing offers both targeted and comprehensive genetic testing options with a gynecologic focus.  With over 10 years of expertise in ovarian cancer risk assessment Vermillion has expertise in cutting-edge research to inform our next generation of products. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection and optimize treatment plans. Visit our website for more information about our products at .

Investor Relations Contact:

Ashley R. Robinson

LifeSci Advisors, LLC

Tel 617-775-5956

EN
04/03/2020

Underlying

VRMLVermillion

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vermillion

 PRESS RELEASE
Free
VRML VERMILLION

Aspira Women’s Health, Inc. to Present at Cantor Virtual Healthcare ...

Aspira Women’s Health, Inc. to Present at Cantor Virtual Healthcare Conference AUSTIN, Texas, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced management will participate in the 2020 Cantor Virtual Healthcare Conference taking place on September 15-17, 2020. Valerie Palmieri, President and Chief Executive Officer, and Robert Beechey, Chief Financial Officer will be available for 1x1 meetings with investors on September 17, 2020.  Conference details are as follows:   Cantor Virtual Healthcare Confe...

September 8, 2020 1 EN
 PRESS RELEASE
Free
VRML VERMILLION

UPDATE – Aspira Women’s Health Reports Second Quarter 2020 Financi...

UPDATE – Aspira Women’s Health Reports Second Quarter 2020 Financial Results Conference Call scheduled for today, August 13th at 4:30 p.m. ET AUSTIN, Texas, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“ASPIRA”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the second quarter ended June 30, 2020. “Despite late first quarter and second quarter challenges from COVID-19, we have delivered strong revenue and volume growth in the first half of 2020 as compared to the first half of 2019. ...

August 14, 2020 1 EN
 PRESS RELEASE
Free
VRML VERMILLION

Aspira Women’s Health Reports Second Quarter 2020 Financial Results

Aspira Women’s Health Reports Second Quarter 2020 Financial Results Conference Call scheduled for today, August 13th at 4:30 p.m. ET AUSTIN, Texas, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“ASPIRA”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the second quarter ended June 30, 2020. “Despite late first quarter and second quarter challenges from COVID-19, we have delivered strong revenue and volume growth in the first half of 2020 as compared to the first half of 2019. In fact, ...

August 13, 2020 1 EN
 PRESS RELEASE
Free
VRML VERMILLION

Aspira Women’s Health, Inc. to Report Second Quarter 2020 Financial ...

Aspira Women’s Health, Inc. to Report Second Quarter 2020 Financial Results on August 13th AUSTIN, Texas, July 31, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced it will report financial results for the second quarter ended June 30, 2020 on Thursday, August 13, 2020 after the market close, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time. Thursday, August 13th @ 4:30pm ETDomestic:201-689-8472International:877-407-4021Conference ID:13706942Webcast: About Aspira Women’s Health Inc...

July 31, 2020 1 EN
 PRESS RELEASE
Free
VRML VERMILLION

Aspira Women’s Health Inc. Announces Equity Financing of Approximate...

Aspira Women’s Health Inc. Announces Equity Financing of Approximately $11 Million AUSTIN, Texas, July 01, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH) (“ASPIRA”), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that investors, including certain affiliates of Jack W. Schuler, ASPIRA’s largest stockholder, have agreed to purchase approximately $11 million of unregistered shares of ASPIRA's common stock in a private placement at a price of $3.50 per share. The closing of the private placement is expected to occur on July 6...

July 1, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch